CClinicalTrials.gg
CompletedNCT03316508Updated Sep 11, 2019

Copeptin- Relevance as a Perioperative Marker in Pediatric Cardiac Surgery

An observational study in Congenital Heart Disease, sponsored by Claudia Herbst. Completed at 1 site in Austria. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Claudia Herbst · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
81
Ages
Up to 6 Years
Sex
All
01

Study summary

This study evaluates the relevance of Copeptin in children with congenital heart disease undergoing cardiac surgery with the need of cardiopulmonary bypass. Three blood samples are taken of each patient. The first and second sample are collected in the operation room before and after the procedure and the third sample on the first postoperative day at the intensive care unit.

Read the detailed description

Objective:

Vasopressin is a hormone secreted by the posterior pituitary gland. Its main functions are constriction of blood vessels and reabsorption of water and thereby regulating water balance and hemodynamics of the body. Copeptin is a cleavage product in the synthesis of vasopressin and is released in equimolar amounts. Its stability makes it easier to determine the amount of vasopressin. It is known, that the use of a heart-lung machine in cardiac procedures has effects on the water balance of the body and may affect the vasopressin secretion.

The aim of this prospective clinical trial is, to figure out if copeptin would be suitable for perioperative risk evaluation in neonates and children with congenital heart disease after surgery with the use of a heart-lung machine.

Hypotheses:

The primary outcome endpoint of this study is the change in copeptin concentration perioperatively in patients with congenital heart disease, with the use of heart-lung machine.

Secondary outcome endpoints are correlations between copeptin concentration and complexity of the procedure (based on the aristotle basic score), clinical status and the perfusion times of the heart-lung machine.

02

Conditions studied

  • Congenital Heart Disease

Keywords

  • copeptin
  • pediatric cardiac surgery
  • heart lung machine
03

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of 81 patients (neonates, infants, children) with congenital heart disease and the need of cardiac surgery with a heart-lung machine. Parental consent after pre-operative consultation and informing about the study is required.

Inclusion criteria

  • ≤6 years of age
  • CHD
  • need of HLM for surgery
  • Informed consent of parents
  • not participating in other studies

Exclusion criteria

Exclusion Criteria:

  • Preoperative ventilatory support
  • Preoperative circulatory support (ECMO, VAD)
  • Diabetes insipidus
  • Preoperative CPR
  • Preoperative shock
  • Preoperative sepsis
  • Preoperative vasopressin application
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
81 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. Change of Copeptin concentrations

    Change of Copeptin concentrations between the baseline and first postoperative measurement

    Time frame: baseline and up to one day

Secondary outcomes

  1. Intubation

    Duration of intubation time

    Time frame: up to one day

  2. Cardiopulmonary bypass

    Total time of cardiopulmonary bypass and aortic cross clamp time.

    Time frame: up to one day

  3. ICU stay

    Length of ICU stay

    Time frame: up to one day

  4. Complexity of procedures

    The surgical complexity of the procedures undergone by the patients will be shown by using a scoring system developed for this purpose named Aristotle Score

    Time frame: up to one day

06

Study locations

1 site
  • Medical University of Vienna
    Vienna, 1090, Austria
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 17, 2017
  • Informed consent form · Apr 27, 2017

Documents are hosted by the registry — open the source record to download them.

08

Registry details

Key details

Study ID
NCT03316508
Lead sponsor
Claudia Herbst
Responsible party
Claudia Herbst (Dr. med. univ., Medical University of Vienna) — Sponsor-investigator
First posted
Oct 20, 2017
Start date
Jun 14, 2017
Primary completion
Oct 1, 2018
Completion
Aug 10, 2019
Last update
Sep 11, 2019

Study contacts

Claudia R Herbst, MD
principal investigator · Medical University Vienna Department for Cardiac Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion